According to a report published by Grand View Research, Inc.; the non-invasive prenatal testing (NIPT) market is likely to reach a valuation of around USD 5.5 billion by 2025. Factors such as increasing demand for non-invasive procedures, launch of new and advanced NIPT products, increasing focus on reimbursement schemes, and increasing maternal age linked with growth in the risk of chromosomal abnormalities in babies can propel the market over the forecast period (2014 to 2025). In addition, increasing awareness regarding prevention and screening of chromosomal anomalies is also expected to increase the demand in the coming years.
Development of prenatal testing in the form of noninvasive tests which acts as an intermediate step between serum screening and invasive diagnostic testing for determining the possibility of fetal abnormality is likely to boost the demand during the forecast period. Adoption of NIPT tests can reduce the expensive and risky invasive procedures like Chorionic Villus Sampling (CVS) and amniocentesis.
Full Research Report On NIPT Market Analysis:
Additionally, coverage expansion offered by payers for average-risk pregnancies is expected to aid in cost-saving on amniocentesis tests and Down’s Syndrome, which is expected to increase the adoption of non-invasive prenatal products. This is estimated to enhance the volumetric capabilities of the market, thereby increasing the overall market revenue. For instance, payers such as Anthem and Blue Shield have launched DNA-based NIPT screening tests for genetic disorders like trisomy 13, 18, and 21 is likely to increase the acceptance rate of these tests. Furthermore, there is less delineation between high and average risk. This is anticipated to improve the volumetric capabilities.
The worldwide non-invasive prenatal testing (NIPT) market can be segmented on the basis of risk-type, gestation period, and regions. As per risk-type, the market can be categorized into high and Average Risk, and low risk. Based on gestation period, the market can be classified into 0 to 12 weeks, 13 to 24 weeks, and 25 to 36 weeks.
Geographically, the market can be divided into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.
In 2015, North America estimated for the largest market share. The growth in the region can be associated with increasing government investment for research and development (R&D). The development of whole-genome sequencing (WGS) is also likely to contribute to regional market growth during the forecast period due to the availability of technologically advanced and well-established healthcare research framework.
View More Reports Of This Category By Grand View Research At:
Asia Pacific is likely to register a robust growth rate due to the growing average maternal age, high occurrence of chromosomal aneuploidies, improving healthcare infrastructure, rising per capita income, and growing awareness programs. The market in the region is also expected to create lucrative growth opportunities during the forecast period. This growth can be associated with the important contribution by countries including China and Japan for technical integration of next-generation sequencing (NGS) procedures and growing development of healthcare, clinical and research and development (R&D) framework in developing countries such as Australia and India. China is anticipated to offer huge opportunities for non-invasive prenatal screening, since, approximately nearly 900, 000 births out of 16 million annual births falls under high risk pregnancies.
Leading players operating in the market include Natera Inc.; F.Hoffmann-La Roche AG; Laboratory Corporation of America Holdings.; Berry Genomics; and LifeCodexx AG.
The participants in the markets are involved in the development and licensing of the software and cloud distribution model in order to expand the technology handover to other laboratories. The players are also emphasizing on gaining the characteristics of established equipment companies and developing lab companies to increase the largest revenue share. The NIPT related price loss in the market is likely to continue in the market. This is expected to increase the competition among the players and also restrict the revenue generation to an extent. Many market participants are focusing towards the analysis of cell-free fatal DNA (cffDNA) from a blood sample collected in the first trimester for developing reliable and accurate NIPT. Since, results obtained in the first trimester after screening are approximately 95% accurate.
Explore the BI enabled intuitive market research database, The Grand Library, by Grand View Research, Inc.
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
For more information: https://www.grandviewresearch.com/
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.
Email: Send Email
Phone: 1-415-349-0058, Toll Free: 1-888-202-9519
Address:28 2nd Street, Suite 3036
City: San Francisco
Country: United States